INTRODUCTION: Cardiovascular disease accounts for almost half of all deaths in individuals with chronic kidney disease stage 5 despite advances in both dialysis treatment and cardiology. A combination of lipid-lowering and anti-inflammatory effects along with avoidance of hypercalcemia should be taken into account when choosing phosphorus binders for maintenance hemodialysis (MHD) patients. METHODS: We examined the association of sevelamer versus calcium-based phosphorus binders with lipid profile, inflammatory markers including C-reactive protein (CRP), and mineral metabolism in MHD patients who participated in the Nutritional and Inflammatory Evaluation of Dialysis Patients (NIED) study from October 2001 to July 2005. RESULTS: Of the 787 MHD patients in the NIED study, 697 were on either sevelamer, a calcium-based binder, or both and eligible for this study. We compared the groups based on taking sevelamer monotherapy (n = 283) or calcium binder monotherapy (n = 266) for serum phosphate control. There were no differences between the groups on dialysis vintage. There were significant differences in age, serum calcium and phosphorus levels, as well as intact parathyroid hormone levels. Using a logistic regression models, the sevelamer group had a higher odds of serum CRP <10 mg/l [odds ratio (OR): 1.06, 95% CI: 1.02-1.11] and LDL cholesterol <70 mg/dl (OR: 1.33, 95% CI: 1.19-1.47) when compared to the calcium binder group independent of age, vintage, body mass index, statin use or other variables. CONCLUSION: The improvements in multiple surrogate markers of inflammation and lipids in the NIED study make sevelamer a promising therapy for treatment in MHD patients with high risk of cardiovascular disease and mortality. 2007 S. Karger AG, Basel
INTRODUCTION:Cardiovascular disease accounts for almost half of all deaths in individuals with chronic kidney disease stage 5 despite advances in both dialysis treatment and cardiology. A combination of lipid-lowering and anti-inflammatory effects along with avoidance of hypercalcemia should be taken into account when choosing phosphorus binders for maintenance hemodialysis (MHD) patients. METHODS: We examined the association of sevelamer versus calcium-based phosphorus binders with lipid profile, inflammatory markers including C-reactive protein (CRP), and mineral metabolism in MHD patients who participated in the Nutritional and Inflammatory Evaluation of Dialysis Patients (NIED) study from October 2001 to July 2005. RESULTS: Of the 787 MHD patients in the NIED study, 697 were on either sevelamer, a calcium-based binder, or both and eligible for this study. We compared the groups based on taking sevelamer monotherapy (n = 283) or calcium binder monotherapy (n = 266) for serum phosphate control. There were no differences between the groups on dialysis vintage. There were significant differences in age, serum calcium and phosphorus levels, as well as intact parathyroid hormone levels. Using a logistic regression models, the sevelamer group had a higher odds of serum CRP <10 mg/l [odds ratio (OR): 1.06, 95% CI: 1.02-1.11] and LDL cholesterol <70 mg/dl (OR: 1.33, 95% CI: 1.19-1.47) when compared to the calcium binder group independent of age, vintage, body mass index, statin use or other variables. CONCLUSION: The improvements in multiple surrogate markers of inflammation and lipids in the NIED study make sevelamer a promising therapy for treatment in MHD patients with high risk of cardiovascular disease and mortality. 2007 S. Karger AG, Basel
Authors: Christian S Shinaberger; Ryan D Kilpatrick; Deborah L Regidor; Charles J McAllister; Sander Greenland; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: Am J Kidney Dis Date: 2006-07 Impact factor: 8.860
Authors: Deborah L Regidor; Joel D Kopple; Csaba P Kovesdy; Ryan D Kilpatrick; Charles J McAllister; Jason Aronovitz; Sander Greenland; Kamyar Kalantar-Zadeh Journal: J Am Soc Nephrol Date: 2006-04 Impact factor: 10.121
Authors: Emiliana Ferramosca; Steven Burke; Scott Chasan-Taber; Carlo Ratti; Glenn M Chertow; Paolo Raggi Journal: Am Heart J Date: 2005-05 Impact factor: 4.749
Authors: Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz Journal: N Engl J Med Date: 2005-07-21 Impact factor: 91.245
Authors: Kamyar Kalantar-Zadeh; Charles J McAllister; Robert S Lehn; Grace H Lee; Allen R Nissenson; Joel D Kopple Journal: Am J Kidney Dis Date: 2003-10 Impact factor: 8.860
Authors: Jessica E Miller; Csaba P Kovesdy; Keith C Norris; Rajnish Mehrotra; Allen R Nissenson; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: Am J Nephrol Date: 2010-09-03 Impact factor: 3.754
Authors: Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier Journal: J Am Soc Nephrol Date: 2015-08-26 Impact factor: 10.121
Authors: Jong Chan Park; Csaba P Kovesdy; Uyen Duong; Elani Streja; Mehdi Rambod; Allen R Nissenson; Stuart M Sprague; Kamyar Kalantar-Zadeh Journal: Hemodial Int Date: 2010-03-24 Impact factor: 1.812
Authors: Jonathan Bazeley; Brian Bieber; Yun Li; Hal Morgenstern; Patricia de Sequera; Christian Combe; Hiroyasu Yamamoto; Martin Gallagher; Friedrich K Port; Bruce M Robinson Journal: Clin J Am Soc Nephrol Date: 2011-08-25 Impact factor: 8.237
Authors: Helen Vlassara; Jaime Uribarri; Weijing Cai; Susan Goodman; Renata Pyzik; James Post; Fabrizio Grosjean; Mark Woodward; Gary E Striker Journal: Clin J Am Soc Nephrol Date: 2012-03-29 Impact factor: 8.237